drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T-cell immunotherapy)
drug_description
Autologous T lymphocytes genetically modified ex vivo to express a chimeric antigen receptor targeting CD123 (IL-3 receptor alpha); infused once post-lymphodepletion to induce targeted cytotoxicity via CAR-mediated activation, proliferation, cytokine release, and perforin/granzyme-dependent killing of CD123+ malignant cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a CD123-specific chimeric antigen receptor. After infusion, CAR engagement of CD123 activates the T cells, driving proliferation, cytokine release, and targeted killing of CD123-positive malignant cells via perforin/granzyme and death-receptor pathways, independent of the native TCR.
drug_name
CART123 (autologous anti-CD123 CAR T cells)
nct_id_drug_ref
NCT06765876